New drug combo aims to tame lupus kidney disease in kids
NCT ID NCT07675291
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether combining rituximab with a low dose of mycophenolate mofetil can safely and effectively treat lupus nephritis in children. Lupus nephritis is a serious kidney complication of lupus. The trial enrolls children aged 3 to 18 with active kidney inflammation. Participants receive the drug combination for six months, and researchers track how well the kidneys respond and whether side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab and mycophenolate mofetil
- What this could lead to
- If successful, this combination could offer a more effective and safer way to control lupus-related kidney disease in children, reducing the need for stronger drugs.
- What could go wrong
- This is a relatively small, early-stage study, so results may not apply to all children. The combination carries risks like infection and immune suppression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a single infusion tame tough lupus?
- Can a smartphone app bridge the lupus care gap for women of color?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Cancer drug shows promise for lupus kidney disease